Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Treasury Shares (2017 - 2025)

Moleculin Biotech's Treasury Shares history spans 9 years, with the latest figure at $64935.0 for Q4 2025.

  • Quarterly results put Treasury Shares at $64935.0 for Q4 2025, up 2112.44% from a year ago — trailing twelve months through Dec 2025 was $64935.0 (up 2112.44% YoY), and the annual figure for FY2025 was $64935.0, up 2112.44%.
  • Treasury Shares for Q4 2025 was $64935.0 at Moleculin Biotech, up from $2935.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $220559.0 in Q4 2021 to a low of $2935.0 in Q4 2024.
  • The 5-year median for Treasury Shares is $64935.0 (2025), against an average of $84564.6.
  • The sharpest move saw Treasury Shares plummeted 96.87% in 2024, then skyrocketed 2112.44% in 2025.
  • Year by year, Treasury Shares stood at $220559.0 in 2021, then plummeted by 81.64% to $40499.0 in 2022, then skyrocketed by 131.85% to $93895.0 in 2023, then plummeted by 96.87% to $2935.0 in 2024, then skyrocketed by 2112.44% to $64935.0 in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $64935.0, $2935.0, and $93895.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.